TY - JOUR
T1 - Antihormone treatment of stage IV breast cancer
AU - Manni, Andrea
AU - Trujillo, Jaime E.
AU - Marshall, James S.
AU - Brodkey, Jerald
AU - Pearson, Olof H.
PY - 1979/2
Y1 - 1979/2
N2 - The antiestrogen Tamoxifen (T), given orally to 113 patients with stage IV breast cancer, induced objective remission in 50%. Duration of remission in the first 39 patients, with minimum 27 months follow up, is 18+ months; these results are equal to those of surgical hypophysectomy. T prolonged survival in responders. Older age, previous response to endocrine therapy and positive estrogen receptors predicted response to T. T was effective in hypophysectomized patients in whom serum growth hormone and prolactin were undetectable, but serum estrogens were present in low amount, suggesting a direct stimulatory effect of estrogens at the tumor level. Hypophysectomy induced further palliation after treatment with T, indicating that pituitary hormones may also play a role in the growth of some human breast cancers. Side effects from T were minimal. T is the initial treatment of choice for postmenopausal women with hormone responsive stage IV breast cancer. Cancer 43:444–450, 1979.
AB - The antiestrogen Tamoxifen (T), given orally to 113 patients with stage IV breast cancer, induced objective remission in 50%. Duration of remission in the first 39 patients, with minimum 27 months follow up, is 18+ months; these results are equal to those of surgical hypophysectomy. T prolonged survival in responders. Older age, previous response to endocrine therapy and positive estrogen receptors predicted response to T. T was effective in hypophysectomized patients in whom serum growth hormone and prolactin were undetectable, but serum estrogens were present in low amount, suggesting a direct stimulatory effect of estrogens at the tumor level. Hypophysectomy induced further palliation after treatment with T, indicating that pituitary hormones may also play a role in the growth of some human breast cancers. Side effects from T were minimal. T is the initial treatment of choice for postmenopausal women with hormone responsive stage IV breast cancer. Cancer 43:444–450, 1979.
UR - http://www.scopus.com/inward/record.url?scp=0018343519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018343519&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(197902)43:2<444::AID-CNCR2820430207>3.0.CO;2-C
DO - 10.1002/1097-0142(197902)43:2<444::AID-CNCR2820430207>3.0.CO;2-C
M3 - Article
C2 - 421171
AN - SCOPUS:0018343519
SN - 0008-543X
VL - 43
SP - 444
EP - 450
JO - Cancer
JF - Cancer
IS - 2
ER -